EBIO will read out Ph3 Bladder Cancer data in May-June/18.
Bladder cancer is a $1B pa commercial opty. A 20% market penetration could lead to a 1.2B MC
As of 3/18, Cash = $25mn with MC = ~$65mn
The initial commercial opty would be ~25K patients (who have failed standard of care and refuse cystecomy). The most recently approved therapy is priced at $37K.
Biotech stocks usually trade 5-10x revenues. At a multiple of 6, EBIO MC would be $1.2B
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.